- Home
- MVBF vs AVIR Comparison
MVBF vs AVIR Comparison
Compare MVBF & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVBF | AVIR |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | 403 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.4M | 434.5M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MVBF | AVIR |
|---|---|---|
| Price | $25.40 | $4.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $29.50 | $10.00 |
| AVG Volume (30 Days) | 28.6K | ★ 285.0K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 34.64 | 3.00 |
| EPS | ★ 0.39 | N/A |
| Revenue | $3,400,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | $64.31 | ★ N/A |
| Revenue Growth | ★ 51.92 | N/A |
| 52 Week Low | $18.71 | $2.78 |
| 52 Week High | $29.59 | $6.45 |
Technical Indicators
Market Signals| Indicator | MVBF | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 24.70 |
| Support Level | $24.78 | $3.32 |
| Resistance Level | $26.81 | $4.34 |
| Average True Range (ATR) | 0.87 | 0.28 |
| MACD | -0.08 | -0.17 |
| Stochastic Oscillator | 53.15 | 6.15 |
Price Performance
Historical ComparisonAbout MVBF MVB Financial Corp.
MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.